Sino-American biotech firm Laekna has announced that it has received clinical trial approval from the US Food and Drug Administration (FDA) for its proprietary monoclonal antibody, LAE102. The molecule is set to be evaluated as a potential treatment for obesity, a condition that affects a significant portion of the global population.
LAE102 is a potent and selective monoclonal antibody targeting ActRIIA, which is expected to offer improved safety over bimagrumab, a drug originally developed by Novartis and later acquired by Eli Lilly. Bimagrumab was co-developed by Dr. Lv, the founder of Laekna, and LAE102 aims to build on this heritage with enhanced safety profiles. In addition to obesity, LAE102 is also being explored for the treatment of metabolic disorders, pulmonary hypertension, and cancer. The drug received IND approval in the US in May 2023 for the treatment of non-small cell lung cancer and a clinical trial filing for obesity or metabolic disorders was submitted in China in March this year.- Flcube.com
